SCHEDULE: BlackRock Boosts MaxCyte Stake to 6.6%

BlackRock, Inc. has disclosed an aggregate beneficial ownership of 6.6% of MaxCyte, Inc.'s common stock as of December 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 6,997,197 shares of MaxCyte, Inc. common stock.
• This represents 6.6% of the total outstanding common stock of MaxCyte, Inc.
• BlackRock holds sole voting power over 6,901,491 shares and sole dispositive power over 6,997,197 shares.
• The filing is an Amendment No. 4 to Schedule 13G, indicating a routine update by an institutional investor.
• BlackRock certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of MaxCyte, Inc.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, contribute to this aggregate ownership.

Sentiment

Score: 5

Explanation: Neutral. The filing is a factual disclosure of institutional ownership and does not contain qualitative information to assess sentiment beyond the fact of a significant holding.

Positives

• Increased institutional investor confidence: BlackRock's continued significant holding (6.6%) indicates a sustained belief in MaxCyte's long-term prospects by a major institutional investor.
• Stability in ownership: The filing is an amendment, suggesting a consistent, long-term investment strategy rather than speculative trading.

Future Outlook

NA

Industry Context

This filing reflects a major asset manager's continued significant investment in the biotechnology sector, specifically in a company like MaxCyte, which operates in the cell engineering and cell therapy space. Such institutional holdings are common for established companies in growth industries.

Comparison to Industry Standards

• BlackRock's 6.6% stake in MaxCyte is a substantial institutional holding, typical for a large asset manager's diversified portfolio.
• Compared to other institutional investors, BlackRock frequently holds significant positions (often 5% or more) in publicly traded companies across various sectors, aligning with its role as a major index fund and active manager.
• This level of ownership is generally considered a vote of confidence, similar to other large institutional investors like Vanguard or State Street, who also routinely disclose significant passive stakes in numerous companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a major institutional holder's stake, potentially signaling confidence.
• Management: Awareness of a significant institutional investor's position, though BlackRock states it's not for control influence.

Key Dates

Keywords

MaxCyte, BlackRock, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Cell Therapy, Investment, Shareholding